Takeda Pharmaceutical (NYSE:TAK) Insider Sells $363,346.99 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 19,651 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $18.49, for a total value of $363,346.99. Following the transaction, the insider directly owned 261,656 shares of the company’s stock, valued at approximately $4,838,019.44. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $2,828,220.30.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $18.17 on Monday. The stock has a market capitalization of $58.22 billion, a P/E ratio of 53.44 and a beta of -0.08. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The firm has a fifty day simple moving average of $16.79 and a two-hundred day simple moving average of $17.18.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.30. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, analysts expect that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in TAK. Private Trust Co. NA lifted its position in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the period. Parkside Financial Bank & Trust grew its position in Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth about $42,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after buying an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.